Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Spero Therapeutics (SPRO) Tax Provisions (2023 - 2024)

Spero Therapeutics (SPRO) has disclosed Tax Provisions for 2 consecutive years, with $290000.0 as the latest value for Q3 2024.

  • For the quarter ending Q3 2024, Tax Provisions fell 86.88% year-over-year to $290000.0, compared with a TTM value of $2.9 million through Sep 2025, changed 0.0%, and an annual FY2023 reading of $2.6 million, changed N/A over the prior year.
  • Tax Provisions was $290000.0 for Q3 2024 at Spero Therapeutics, down from $387000.0 in the prior quarter.
  • Across five years, Tax Provisions topped out at $2.2 million in Q3 2023 and bottomed at $290000.0 in Q3 2024.